Long-term follow-up of bone density in women with primary ovarian insufficiency

Menopause

Volumn 22, Issue 9, 2015, Pages 946-949

  Benetti Pinto, Cristina Laguna ^a   Ferreira, Valeska B ^a   Yela, Daniela A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Bone mineral density; Hormone therapy; Hypoestrogenism; Osteoporosis; Primary ovarian insufficiency

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; GESTAGEN;

ADULT; ARTICLE; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FEMALE; FEMUR NECK; FOLLOW UP; HORMONAL THERAPY; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PREMATURE OVARIAN FAILURE; BRAZIL; COHORT ANALYSIS; MENOPAUSE; PHOTON ABSORPTIOMETRY; RADIOGRAPHY;

ABSORPTIOMETRY, PHOTON; ADULT; BONE DENSITY; BRAZIL; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENOPAUSE; OSTEOPOROSIS; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84956914351     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000445     Document Type: Article

References (35)

1. Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med 2009; 360: 606-614
2. Finkelstein JS, Brockwell SE, Mehata V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocriol Metab 2008; 93: 861-868
3. Imai Y, Youn MY, Kondoh S, et al. Estrogens maintain bone mass by regulation expression of genes controlling function and life span in mature osteoclasts. Ann N Y Acad Sci 2009; 1173(suppl 1): E31-E39
4. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor a and induction of Fas ligand in osteoclasts. Cell 2007; 130: 811-823
5. Marin G, Domené HM, Barnes KM, Blackwell BJ, Cassorla FG, Cutler GB Jr. The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab 1994; 79: 537-541
6. Anasti JN. Premature ovarian failure: an update. Fertil Steril 1998; 70: 1-15
7. Uygur D, Segul O, Baydar D, et al. Bone loss in young women with premature ovarian failure. Arch Gynecol Obstet 2005; 273: 17-19
8. Asli IN, Fallahaian M, Seddigh HR, Javadi H, Baharfar N, Assadi M. Evaluation of bone mineral density in premature ovarian failure. Hell J Nucl Med 2010; 13: 261-263
9. Hadjidakis DJ, Kokkinakis EP, Sfakianakis ME, Raptis SA. Bone density patterns after normal and prematuremenopause. Maturitas 2003; 44: 279-286
10. Leite-Silva P, Bedone A, Pinto-Neto AM, Costa JV, Costa-Paiva L. Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure. Arch Gynecol Obstet 2009; 280: 177-181
11. Benetti-Pinto CL, Bedone A, Magna LA, Marques-Neto JF. Factors associated with the reduction of bone density in patients with gonadal dysgenesis. Fertil Steril 2002; 77: 571-575
12. Meczekalski B, Podfigurna-Stopa A, Genazzani AR. Hypoestrogenism in young women and its influence on bone mass density. Gynecol Endocrinol 2010; 26: 652-657
13. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-1010
14. Crofton P, Evans N, Bath E, Warner P, Whitehead TJ, Critchley HO, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol 2010; 63: 707-714
15. Papagianni V, Deligeoroglou E, Makrakis E, et al. Response to hormonal treatment of young females with primary of very premature ovarian failure. Gynecol Endocrinol 2011; 27: 291-299
16. Castelo-Branco C, Rovira M, Pons F, et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 1996; 23: 307-312
17. Mittal M, Kreatsa M, Narvekar N, Savvas M, Hamoda H. Fertility desires, choice of hormone replacement and the effect of length of time since menopause on bone density in women with premature ovarian insufficiency: a review of 223 consecutive new referrals to a tertiary centre. Post Reprod Health 2014; 20: 104-111
18. Sugimoto AK, Hodsman AB, Nisker JA. Long-Term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. Fertil Steril 1993; 60: 672-674
19. Ohta H, Sugimoto I, Masuda A, et al. Decreased bone mineral density associated with early menopause progresses for at least ten years: crosssectional comparisons between early and normal menopausal women. Bone 1996; 18: 227-231
20. Hadjidakis D, Kokkinakis E, Sfakianakis M, Raptis SA. The type and time of menopause as decisive factors for bone mass chances. Eur J Clin Invest 1999; 29: 877-885
21. Murthy V, Chamberlain RS. Menopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution. Cancer Control 2012; 19: 317-329
22. Rafique S, Sterling EW, Nelson LM. A new approach o primary ovarian insufficiency. Obstet Gynecol Clin North Am 2012; 39: 567-586
23. Panay N, Kalu E. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol 2009; 23: 129-140
24. Rebar RW, Conolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990; 53: 804-810
25. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-Term health consequences. Maturitas 2010; 65: 161-166
26. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16: 15-23
27. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ III. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006; 7: 821-828
28. Bedaiwy M, Casper R. Treatment with leuprolide acetate and hormonal add-back for up 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril 2006; 86: 220-222
29. Shifren JL, Gass ML. The North American Menopause Society recommendations for clinical care of midlife women. Menopause 2014; 21: 1038-1062
30. Rosen C. Clinical practice. Postmenopausal osteoporosis. N Engl J Med 2005; 353: 595-603
31. Bath LE, Critchley HO, Kelnar CJ, Wallace WHB. Choice of hormone therapy in young women with premature ovarian failure. Clin Endocrinol (Oxf ) 2001; 55: 697-698
32. Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005; 92: 1293-1297
33. Mittal M, Savvas M, Narvekar N, Panay N, Hamoda H. A cross-sectional national questionnaire survey assessing the clinical attitudes of members of the British Menopause Society to the management of women with premature ovarian insufficiency. Post Reprod Health 2014; 20: 90-97
34. Vujovic S, Brincat M, Erel T, et al; European Menopause and Andropause Society. EMAS position statement: managing women with premature ovarian failure. Maturitas 2010; 67: 91-93
35. Benetti-Pinto CL, Brancalion MF, Assis L, et al. Mammographic breast density in women with premature ovarian failure: a prospective analysis. Menopause 2014; 21: 933-937